ES2172937T3 - 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. - Google Patents

21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.

Info

Publication number
ES2172937T3
ES2172937T3 ES98956833T ES98956833T ES2172937T3 ES 2172937 T3 ES2172937 T3 ES 2172937T3 ES 98956833 T ES98956833 T ES 98956833T ES 98956833 T ES98956833 T ES 98956833T ES 2172937 T3 ES2172937 T3 ES 2172937T3
Authority
ES
Spain
Prior art keywords
oxidoprogesterone
hydroxi
glucocorticoids
treat
excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956833T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Pedro Lantos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2172937T3 publication Critical patent/ES2172937T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

21-Hidroxi-6,19-oxidoprogesterona de fórmula I para uso como medicamento.
ES98956833T 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. Expired - Lifetime ES2172937T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (en) 1997-09-23 1997-09-23 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid

Publications (1)

Publication Number Publication Date
ES2172937T3 true ES2172937T3 (es) 2002-10-01

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956833T Expired - Lifetime ES2172937T3 (es) 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.

Country Status (13)

Country Link
US (1) US6303591B1 (es)
EP (2) EP0903146A1 (es)
AR (1) AR023008A1 (es)
AT (1) ATE215373T1 (es)
AU (1) AU738522B2 (es)
CA (1) CA2303817C (es)
DE (1) DE69804659T2 (es)
DK (1) DK1033990T3 (es)
ES (1) ES2172937T3 (es)
IL (1) IL135232A (es)
PT (1) PT1033990E (es)
WO (1) WO1999015181A1 (es)
ZA (1) ZA988674B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1042889B (zh) 1999-04-30 2006-12-29 辉瑞产品公司 糖皮质激素受体调制剂
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
DK1325022T3 (da) 2000-09-18 2007-02-19 Applied Research Systems Fremgangsmåde til fremstilling af 21-hydroxy-6,19-oxidoprogesteron (21OH-6OP)
SI1330468T1 (sl) * 2000-09-18 2007-10-31 Serono Lab Ĺ˝veplovi analogi 21-hidroksi-6,19-oksido-progesterona (21oh-6op) za zdravljenje preseĺ˝ka glukokortikoidov
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
PL2576582T3 (pl) * 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
HUE052574T2 (hu) 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
JP2022515528A (ja) * 2018-12-28 2022-02-18 パンダ コンサルティング エルエルシー 短時間作用型選択的糖質コルチコイド受容体モジュレーター
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途

Also Published As

Publication number Publication date
EP1033990B1 (en) 2002-04-03
EP1033990A1 (en) 2000-09-13
CA2303817C (en) 2008-04-01
DK1033990T3 (da) 2002-07-08
US6303591B1 (en) 2001-10-16
ZA988674B (en) 1999-06-28
CA2303817A1 (en) 1999-04-01
ATE215373T1 (de) 2002-04-15
IL135232A0 (en) 2001-05-20
WO1999015181A1 (en) 1999-04-01
PT1033990E (pt) 2002-07-31
AU1334199A (en) 1999-04-12
AU738522B2 (en) 2001-09-20
AR023008A1 (es) 2002-09-04
DE69804659T2 (de) 2002-10-02
EP0903146A1 (en) 1999-03-24
IL135232A (en) 2005-05-17
DE69804659D1 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
MX9700885A (es) Nuevas heteroariloxazolidinonas.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
HN1999000124A (es) Derivados de pirazol substituido.
DOP2000000109A (es) Derivados de tiazolilamida
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
IT1285770B1 (it) Composti corticoidei
ES2183180T3 (es) Nuevos derivados de guanidina, procedimientos para su preparacion y su uso como medicamento.
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY26133A1 (es) Derivado sustituido de pirazol.
BR0110087A (pt) Compostos para modular proliferação celular
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
BR0016781A (pt) Bases de 1-naftol e 2-naftol - mannich substituìdas
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
ATE275551T1 (de) Halogenpyrimidine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1033990

Country of ref document: ES